Development and evaluation of a combined x-RAY transmission and diffraction imaging system for pathology
Ended Project Grant Awarded Last action
- Award ID
- R44EB034645
- Recipient
-
Quadridox Inc. UEI J8EKVLUY96J9
- Awarding agency
-
National Institute of Biomedical Imaging and Bioenginering
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,585,816
Award facts
- Assistance listing
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- Completion date
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pathology, which plays a vital role in clinical diagnosis, faces numerous challenges that impact its efficacy. For example, resected specimens often require preparing and analysis of as many as 30-40 slide blocks under a microscope until the disease is confirmed; selection of slices for slide preparation uses subjective methods such as palpation, which depend greatly on the skill of the individual performing the assessment and introduces inconsistency in the clinical process; and for each slide block examined, analysis and annotation requires manual observation of every microscopic region of the tissue. As a result, most pathology evaluations often take 1-3 weeks to analyze samples and reach a conclusion regarding potential cancers. An added challenge is that insurance reimbursements are capped per case regardless of the number of slide blocks processed, with any additional costs being absorbed by the hospital. Consequently, hospitals must balance the trade-off between minimizing the number of slices (for economic viability) and not compromising diagnostic care. These challenges affect not only clinical pathology but also research involving pathology specimens and tissue selection for biobanking. There is a critical need to eliminate subjectivity, reduce pathologists' workload, and increase throughput in histological analysis. We propose to meet this need by developing a new technology called x-RAY diffraction imaging (xrdi), which can scan any number of surgically resected, sliced pathology specimens and automatically indicate the likelihood and location of disease in each slice within minutes. In collaboration with duke university, we previously built a research prototype xrdi system and demonstrated its utility by scanning and evaluating 300 breast cancer slices with high accuracy and resolution. In this direct-to-phase-II sbir application, we will now construct a new clinical version of the xrdi scanner that is affordable, reliable, and accurate, and can be directly integrated into the clinical pathology workflow. We will build the scanner, test and evaluate its performance, and demonstrate its utility through field-testing in collaboration with clinical pathology laboratories in the US. This project will provide a first-of-its-kind, commercially feasible xrdi scanner for rapid, non-destructive imaging of pathology specimens with the ability to inform pathologists about the presence and location of cancer within the different tissue slices. The proposed clinical scanner will enable: 1) analysis of the whole slice volume of the specimen rather than a few microns at the surface of a subset of the slices, which is the current standard of care process using microscopy, 2) quantitative identification of disease based on XRD information obtained directly from the tissue, and 3) slice selection based on quantitative, reproducible measurements, thereby eliminating user-related subjectivity. Importantly, IT would significantly speed up pathology workflow, providing decisions within hours instead of days, and improve the productivity and profitability of pathology labs by reducing the number of slide blocks analyzed per case.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $923,685 | |
| Amendment | $923,685 | |
| Amendment | -$12,248 | |
| Amendment | -$12,248 | |
| Amendment | -$12,248 | |
| Amendment | $887,595 | |
| Original award | $887,595 |
Quick answers
Who received award R44EB034645?
R44EB034645 was awarded to Quadridox Inc. by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on September 8, 2023.
How much is award R44EB034645 worth?
$3,585,816 has been obligated on R44EB034645.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award